Genetic Testing May Increase Fear of Recurrence

Podcast

It is well known that fear of recurrence is a major issue in the cancer community, but can genetic test results outlining risk impact those feelings?

It is well known that fear of recurrence is a major issue in the cancer community, but can genetic test results outlining risk impact those feelings?

For this episode of “The Vitals,” we spoke with Maurade Gormley, CPNP, RN, assistant professor and post-doctoral fellow at the NYU Rory Myers College of Nursing. Her recent research analyzed how Oncotype DX genomic test results may increase fear of recurrence in breast cancer survivors.

Recent Videos
Image of a woman with a white shirt in front of an Oncology Nursing News branded backdrop
Photo of a man with glasses in a suit in front of an Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of a woman with glasses wearing a striped blouse and a black sweater in front of an Oncology Nursing News branded backdrop
Photo of Jamie Carroll, APRN, CNP, MSN, from a video call with an Oncology Nursing News branded border around the frame
Image of Kayle Freeman, DNP, APRN, FNP-C, in a video call with an Oncology Nursing News border around the frame
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of Pattie Jakel, MN, RN, AOCN, in front of a blue watercolor Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Medium closeup shot of a women in front of a dark blue background with graphics that read "All in Against Cancer" and "Ochsner Health"
Related Content
Side profile anatomical rendering of a person, with breast tissue and a breast tumor in orange

Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype

Ashley Chan
March 25th 2025
Article
The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Illustration of small patient and provider characters surrounded by larger technology devices with medical information coming off of the screens and other medical props nearby

Mobile App May Be Feasible for Tracking Oral Cancer Medication Adherence

Bridget Hoyt
March 10th 2025
Article

Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at baseline saw some increase in adherence.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Blue rendering of a person with breast tissue highlighted in orange

T-DM1 Further Improves DFS and OS vs Trastuzumab in HER2-Positive Early Breast Cancer

Bridget Hoyt
February 20th 2025
Article

T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.

Blue image of a breast with tissue and a tumor highlighted in orange

KN026-Docetaxel Combo Shows Efficacy, Safety in HER2+ Metastatic Breast Cancer

Ashling Wahner
February 17th 2025
Article

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.